II. Indications
- FDA Approved
- Hodgkin Lymphoma
- Melanoma (metastatic)
- Off-Label
- Medullary Thyroid Cancer
- Panceatic Neuroendocrine Masses
- Pheochromocytoma (malignant)
- Soft Tissue Sarcoma
III. Mechanism
- See Alkylating Agent
- Triazene derived antineoplastic
- Prodrug that is metabolized in the liver to the active MTIC (monomethyl triazeno imidazole carboxamide)
- Similar to Temozolomide, which is metabolized to MTIC at physiologic pH
- Acts as an DNA Alkylating Agent, cross-linking DNA and blocking cell function and replication
IV. Dosing
- See other references for disease specific dosing protocols
V. Adverse Effects
- Alopecia
- Bone Marrow Suppression
- Gastrointestinal (Nausea, Vomiting, Anorexia)
- Hepatotoxicity
- Secondary Malignancy
-
Soft Tissue Injury on extravasation
- May result in severe local tissue necrosis
VI. Safety
- Avoid in Lactation
- Avoid in Pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring
VII. Resources
- Dacarbazine Powder for Injection Solution (DailyMed)
- Dacarbazine (LiverTox)